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Abstract. Widespread availability of monotherapies and falsified antimalarials is thought to have contributed to the
historical development of multidrug-resistant malaria in Cambodia. This study aimed to document the quality of
artemisinin-containing antimalarials (ACAs) and to compare two methods of collecting antimalarials from drug outlets:
through open surveyors and mystery clients (MCs). Few oral artemisinin-based monotherapies and no suspected falsified
medicines were found. All 291 samples contained the stated active pharmaceutical ingredient (API) of which 69% were
considered good quality by chemical analysis. Overall, medicine quality did not differ by collection method, although
open surveyors were less likely to obtain oral artemisinin-based monotherapies thanMCs. The results are an encouraging
indication of the positive impact of the country’s efforts to tackle falsified antimalarials and artemisinin-based mono-
therapies. However, poor-quality medicines remain an ongoing challenge that demands sustained political will and
investment of human and financial resources.
INTRODUCTION
Historically, the Thai–Cambodia border has been a focal
point for the development of antimalarial resistance.1 In
response to the development of multi-drug resistant malaria,
in 2000, Cambodia became the first countries to make
artemisinin-based combination therapy (ACT), the national
first-line treatment of uncomplicated Plasmodium falciparum
(Pf) malaria. Since co-formulated ACTs were not commer-
cially available at the time, artesunate and mefloquine were
imported and packaged as age–weight-specific co-blister packs
by the Cambodian Ministry of Health with support from the
World Health Organization (WHO). These medicines were
provided for free through public health facilities as “A + M”
and socially marketed at a subsidized price through private
sector under the brand name Malarine in recognition of the
important role the private sector plays as a source of antima-
larial treatment.2–6
In 2008, evidence of artemisinin-resistant Pf was reported
on the Thai–Cambodia border.7,8 The repeated emergence of
antimalarial drug resistance in this area is likely to be due to a
number of contributing factors including the genetic epidemi-
ology of the parasite itself.9 However, drug pressure exerted
on the parasite population over time is likely to be a key
driver. Drug pressure selects for relatively resistant parasites
particularly when parasites are exposed to an antimalarial on
its own as a monotherapy and to subtherapeutic concentra-
tions. Subtherapeutic concentration of drugs can be due to
different factors. The dose prescribed or sold by the provider
may be inadequate; the right dose might be prescribed but
poorly adhered to by the patient; there may be poor bioavail-
ability; or the medicine may be of poor quality, containing
inadequate doses of the active pharmaceutical ingredi-
ent (API).
As well as contributing to the development of drug resis-
tance, poor quality medicines also have a direct effect on the
patients who take them and can lead to treatment failure,
severe disease and death as well as increased economic bur-
den. Medicines may be of poor quality at time of purchase for
a number of reasons. They may be falsified medicines (also
known as spurious/falsely labeled/falsified/counterfeit [SFFC])
that are deliberately and fraudulently mislabeled, with respect
to identity and/or source; they may be substandard medicines
that are produced by manufacturers authorized by regulatory
authorities, but which do not meet quality specifications stan-
dards set for them10; or they may be medicines manufactured
according to quality specifications but which have degraded
during transport and storage.
Falsified medicines have achieved most attention and the
presence has been widely reported globally11–15 and in tropi-
cal countries, antimalarials have been particularly targeted by
criminals.16,17 Studies in southeast Asia previously reported
widespread availability of falsified “artesunate” containing no
active ingredient and with up to 16 versions of the falsified
holograms on the packaging.4,18 However, most of previous
studies have not used random sampling and therefore in most
cases the actual prevalence of falsified and poor-quality anti-
malarials is unknown.19
In Cambodia, falsified medicines as well as artemisinin-based
monotherapies have previously been widely reported.20–24 Since
then, there have been many initiatives focused on cracking
down on poor-quality medicines including as a key component
of the recent Artemisinin Resistance Containment program.25
To reduce drug pressure, a ban on oral artemisinin-based mono-
therapies was implemented, as strengthening of the drug regula-
tory and enforcement capacity.25–27 “containment zones” were
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defined, according to the level of drug resistance suspected
and the first-line treatment of Pf malaria was switched from
co-blistered artesunate and mefloquine to co-formulated
dihydroartemisinin–piperaquine starting with Zone 1 in 2010,
and later nationwide.
Recent surveys in Cambodia suggest that there has been a
significant decrease in the availability of oral artemisinin-
based monotherapies in the private sector.6 However, there
are little recent data on the prevalence of poor-quality anti-
malarials. The primary aim of this study was therefore to pro-
vide robust estimates of the quality of artemisinin-containing
antimalarials (ACAs) available in Cambodia and an examina-
tion of the risk factors associated with poor quality. In addi-
tion, despite guidelines,28 it is not clear what is the most
suitable approach for procuring medicine samples for the
analysis of drug quality. The secondary objectives of this study
included a comparison of alternative approaches to procuring
drugs by comparing the type and quality of malaria treatments
bought through open interviews of private providers with those
purchased covertly by mystery clients (MCs).
METHODS
Study design. This study was carried out in malaria-
endemic areas of Cambodia as part of a study which used a
mixed methods approach to studying how antimalarial drugs
and malaria rapid diagnostic tests (mRDTs) are used in the
private sector. The study included a census survey of private
providers, MC study, observational study of the use of
mRDTs and the quality of mRDTs transported and stored
under field conditions.29 In this paper, we report the findings
of the laboratory analysis of ACAs collected during the cen-
sus survey and MC study. We define ACAs as any drug con-
taining an artemisinin derivative (i.e., artesunate, artemether,
artemisinin, or dihydroartemisinin) either as a monotherapy
or in combination with a partner drug.
Results from the analysis of mRDT quality will be pre-
sented separately.
Site selection. The primary sampling unit for the selection
of outlets was the “Health Centre Catchment Area”— the
town and villages within the catchment areas of the health
center. Health centers in Cambodia with more than 100
malaria cases in the previous year were stratified into those
within containment areas (i.e., Zone 1 or 2, N = 55) or the
noncontainment area (i.e., Zone 3, N = 29). From each strata,
six health centers were randomly selected using a random
number generator resulting in 12 health centers in total
representing 10.9% (6/55) and 20.7% (6/29) of the eligible
health center catchment areas.
Inclusion criteria. Any private provider who supplied anti-
malarial medicines and/or blood tests for malaria was eligible
for inclusion in the survey. This included facilities with quali-
fied health-care workers (e.g., nurses and pharmacists), some
of whom also worked in public health facilities, as well as
drug shops and grocery shops staffed by untrained sellers.
Attempts were made to distinguish and select only “regis-
tered” or “trained” providers; however, this proved difficult
due to the absence of up-to-date lists of such providers.
Sample and data collection. The study was conducted
between November 2010 and January 2011. At each of the 12
health center catchment areas, the census survey teams visited
the relevant local authorities to obtain lists of the names and
location of known health facilities and outlets. The surveyors
then tried to visit all the identified providers and in addition,
visited any other providers who identified locally as being
potential sources of antimalarials, including general stores
and mobile providers.
The MC study was conducted during the same period as the
overt census survey in all the selected health center catchment
areas except one where dangerous roads made the district inac-
cessible in the interval between the census team and MC visits.
Two nearby health center catchment areas were included in the
MC study at the request of local authorities: Sala Krau in Pailin
and Sotnikum in Siem Riep. In each health center catchment
area, the MC study team attempted to visit all the legible
outlets visited by the census study team. In one peri-urban area
where there were a large number of providers and logistic
constraints restricted the numbers that could be included in
the MC study, 16 outlets were selected from the surveyor’s list
using a random number generator. The interval between the
overt census survey and MC study was between 5 and 21 days.
The census survey was carried out by three teams of three
or four surveyors and two supervisors. The MC study was
carried out by a single team composed of two research assis-
tants, three MC actors, and a supervisor. Surveyors and MC
research assistants were given 1 week training including field-
based practice. The three actors were local adult Khmer
males who were given 3 days training to dress and act out
scenarios as if they were forest workers, the main risk group
for malaria in Cambodia.
In the census survey, surveyors obtained informed written
consent from the most senior person in the outlets, and then
used a structured questionnaire to collect information about
the availability of antimalarials and mRDTs, the qualification
of providers and their opinions and self-reported practice with
regard to antimalarials and diagnosis. Observations were
about the appearance of the outlet and also the medicine
storage conditions. Based on surveyors’ observations, outlets
were categorized into different types based on size, types of
goods and services provided, and presence of signs and certif-
icates. Each outlet was georeferenced and samples of all
ACAs that were offered were purchased, labeled, and sent
for laboratory analysis.
During the MC study, the MCs presented themselves to
each selected private provider either as patients themselves
with symptoms of malaria or on behalf of a sick friend or
relative. They were instructed to initially only give symptoms
of malaria (fever, headache, body pain, chills) and to observe
what the provider did and said, and to buy any medicines ini-
tially offered, before providing progressively more information
eventually aimed specifically at trying to buy an artemisinin-
based monotherapy. Immediately after the interaction, the MC
was debriefed by a research assistant who audiotaped the
debriefing and filled in a semistructured questionnaire.
All data collection tools were translated into Khmer and back
translated to English, piloted and revised a number of times.
Ethical approval and permissions. Ethical approval for the
study was granted from the National Ethics Committee for
Health Research in Cambodia and the London School of
Hygiene and Tropical Medicine Ethics Committee, United
Kingdom (Ref: 5970). Results were reported to the Ministry
of Health and relevant partners.
Data entry and analysis. Data were double entered in
Microsoft Excel and checked for coding errors and consistency.
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Textual data were translated from Khmer into English and the
two data sets were compared and inconsistencies if present
resolved. Data analysis was conducted using STATA 11 (Stata
Corp., College Station, TX) and Microsoft Excel.
Since there is no single accepted standard range for defin-
ing drugs as being poor quality in terms of %API, for the
purposes of this paper, ACAs were defined as being poor
quality if they contained < 85% or ³ 115% of the stated API.
This follows the recommendations by the U.S. Pharmacopeia
Convention for the analysis of single-tablet samples. Identifi-
cation of potential counterfeit medicines was based on pack-
aging inspection and if chemical analysis identified either very
low levels of API (< 20%) or the presence of other APIs.
Analysis of degradation products was not performed on these
samples, therefore, it was not possible to differentiate between
medicines that were poor quality due to poor manufacturing
practice versus degradation postmanufacture.
To identify predictors related to poor quality, c2 tests were
first performed using a univariate logistic regression model,
with the effect of outlet and antimalarial associated character-
istics on the outcome estimated using a Mantel–Haenszel test
for comparing odds ratios (ORs). To increase statistical
power and simplify interpretations, multilevel categorical var-
iables were collapsed into binary ones. All variables with a
P value £ 0.25 in the bivariate analysis were included in the
multiple logistic regression model after they were checked for
colinearity. Remaining nonsignificant predictors were intro-
duced one at a time to detect for additional confounders.
These remained in the model if the OR of other predictors in
the model changed by greater than 20%. P values were
adjusted for clustering at the district level and for stratifica-
tion by containment zone using the STATA svy command.
Sample and data handling. All purchased medicines were
labeled, stored, and transported under appropriate shipping
conditions to Phnom Penh and then to the ACT Consortium
Drug Quality project analytical laboratories in the United
Kingdom and United States. Each sample was logged and
labeled with a unique barcode linking it to a database con-
taining detailed description of the packaging as well as details
about the drugs.
Packaging and laboratory analysis. The packaging of each
sample was scanned electronically and/or photographed. Anal-
ysis of the packaging was conducted by inspecting the package
and comparing against authentic packaging wherever available.
Tablets were analyzed for the amount of API present using
high-performance liquid chromatography (HPLC). HPLC anal-
yses were conducted by pulverizing the tablets and extracting
them in an appropriate solvent; artesunate and dihydroar-
temisinin were dissolved in methanol; mefloquine samples
were dissolved in methanol/2.0 N hydrochloric acid (MeOH/
2.0 N HCl; v/v) and piperaquine samples were dissolved in
methanol/0.1 M HCl (1:1; v/v). Solvent extracts were sonicated
followed by centrifuging, and the supernatant injected into the
HPLC system for determining the amount of API present.
Injectables (where the stated API carrier was coconut oil) were
dissolved in methanol prior to HPLC.
HPLC using a Dionex Ultimate 3000 system (Thermofisher,
Hemel Hempstead, United Kingdom) and separation was
achieved using a GENESIS AQ 4 mm column (150 + 4.6 mm,
Grace Materials Technologies, Cranforth, United Kingdom).
The mobile phase was a gradient of ammonium formate
(10 mM, pH 2.7) and acetonitrile (v/v; 60:40–85:15 over
7.0 minutes). A photodiode array unit (UV-PDA; DAD 3000,
Thermofisher, Hemel Hempstead, UK) set at 204 nm for the
Figure 1. Map of the operational districts in which the study took place.
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artemisinin derivatives, 360 nm for piperaquine, and 259 nm for
mefloquine was used as the detector. In all cases, the flow rate
used was 1.0 mL/min. Calibration curves of each compound
were generated by Dionex Chromeleon 7.2 chromatography
data system software (Thermofisher, Hemel Hempstead, UK)
using known amounts of the corresponding chemical standard
(obtained from Sigma Aldrich, United Kingdom and Roche,
Basel, Switzerland).
Samples were also sent to Georgia Institute of Technology,
Atlanta, GA and the U.S. Centers for Disease Control and
Prevention Laboratories, Atlanta, GA for HPLC confirma-
tory analysis and mass spectrometry screening, respectively.
Additional laboratory analysis details are available on request.
RESULTS
General description. The randomized selection of health
center catchment areas resulted in the six being within the
containment zone strata all being in different provinces:
Battambang, Pailin, Kampot, Oddar Meanchey, Preah Vihear,
and Siem Riep. Outside of the containment zone, three of the
six randomly selected health center catchment areas were in
Kratie province and the other three were in Rattanakiri,
Mondulkiri, and Kampong Thom provinces (Figure 1).
In the census survey, a total of 430 outlets were screened.
Two hundred and three outlets, reportedly sold antimalarial
drugs of which 181 (89.2%) sold an ACA. The most common
type of outlets was pharmacies (28.1%, N = 61) and grocery
shops (25.3%, N = 55). In the MC study, a total of 211 inter-
actions were conducted; these took place in 190 out of 203
(93.1%) outlets that were identified as selling antimalarial
drugs during the census survey. A further 21 interactions were
from the two health center catchment areas that were included
in the MC study but not in the census. In the MC study, after
the initial interaction, MCs were offered some medicines in
three quarters of the cases (76.7%, 161/210), of which only
19.9% (32/161) were apparently for “malaria.” After the initial
interaction, 86.3% (182/211) of MCs then gave more informa-
tion to convince the provider to sell them an antimalarial,
after which 45.6% (83/182) bought drugs that were apparently
for malaria.29
Description of the ACAs. Overall 291 ACAs were bought
and analyzed, 212 ACAs from the census survey and 79 from
the MC survey (Table 1). The most common ACA was the
co-blistered artesunate and mefloquine, especially Malarine,
the co-blistered product, manufactured by Cipla in India and
socially marketed by Population Services International.
In the census survey, co-blistered artesunate and meflo-
quine accounted for three quarters (72.6%, 154/212) of ACAs,
Table 1
Type of antimalarials analyzed by stated INN, stated brand name, stated manufacturer, and method of collection
Stated INN and formulation Stated brand name (stated manufacturer) MC collection n (%) Census survey collection n (%)
Artesunate +Mefloquine
co-blistered tablets
A +M − 15
(Unknown) 6 (7.6) 14 (6.6)
(Cipla for PSI) 3 (3.8) 1 (0.5)
(Roll Back Malaria) 1 (1.3) 0 (0.0)
Malarine − −
(Unknown) 35 (44.3) 135 (63.7)
(Cipla for PSI) 4 (5.1) 4 (1.9)
Artesunate +Mefloquine
co-formulated tablets
A +M − −
(Farmanghuinos) 1 (1.3) 0 (0.0)
Artesunate tablets Arquine 50 − −
(MS) 3 (3.8) 2 (0.9)
Artesunat − −
(Cong Ty Phan Duqc Pham Djch
Vu Y Tekhanh nqi)
0 (0.0) 1 (0.5)
(Unknown) 3 (3.8) 1 (0.5)
Artesunate − −
(Bindinh Pharma) 7 (8.9) 4 (1.9)
(Canapharm) 1 (1.3) 1 (0.5)
(Unknown) 3 (3.8) 3 (1.4)
Artemether injection Artemedine − −
(Kunming Pharmaceutical Corp) 0 (0.0) 1 (0.5)
Artemether − −
(Shanghai Pharmaceutical
Industrial Corps)
0 (0.0) 18 (8.5)
(Rotexmedica GmBH distributed
by Dafra Pharmaceutical Corp)
1 (1.3) 0 (0.0)
Artesiane 80 − −
(Unknown) 0 (0.0) 1 (0.5)
(Rotexmedica GmBH distributed
by Dafra Pharmaceutical Corp)
1 (1.3) 14 (6.6)
Artemisinin/piperaquine
co-formulated tablets
Artequick − −
(Artepharm Co. Ltd) 0 (0.0) 8 (3.8)
(Unknown) 7 (8.9) 3 (1.4)
Dihydroartemisinin/piperaquine
coformulated tablets
Duo-cotecxin − −
(Zhejian Holley Nanhu) 3 (3.8) 0 (0.0)
Dihydroartemisinin tablets Cotecxin − −
(Beijing Holley-Cotec) 0 (0.0) 1 (0.5)
Total 79 (100) 212 (100)
INN = international non-proprietary name; MC = mystery client; MS = medical supply.
42 YEUNG AND OTHERS
with the adult dose form of Malarine accounting for 54.7%
(116/212) (Figure 2). Injectable artemether, the first-line treat-
ment of severe malaria, was the next most prevalent ACA
(16.0%, 34/212), followed by oral artesunate monotherapy
(5.7%, 12/212), and oral artemisinin co-formulated with
piperaquine (5.2%, 11/212).
During MC visits, the MCs bought whatever medicines
were offered, including packets containing a mix of drugs
(“drug cocktails”) as well as whole packets of antimalarial
medicines. A total of 190 cocktail packets were bought, of
which 112 (58.9%) contained an antimalarial, 34 of which
were ACAs. In addition, 45 ACAs were bought as complete
blister packets, so that in all 79 ACAs were purchased. As in
the census survey, the most common ACA form was as the
adult dose form of Malarine (43.0%,N = 34/79). However, the
next most common ACA was oral artesunate monotherapy
(41.7%,N = 67/79), followed by oral artemisinin co-formulated
with piperaquine (8.9%, N = 7), oral dihydroartemisinin
co-formulated with piperaquine (3.8%, N = 3), and only two
samples of injectable artemether.
There was a significantly lower likelihood of buying
artesunate monotherapy through the overt surveyor approach
compared with the MC (odds ratio [OR]: 0.2, 95% confidence
interval [CI]: 0.09, 0.52, P = 0.0001). Conversely, there was a
higher likelihood of buying injectable artemether through the
overt survey, compared with the MC (OR: 7.45, 95% CI: 1.82,
65.26, P = 0.002).
Although there was a trend toward artesunate monother-
apy being more likely to be sold in the non-containment area
(N = 20) compared with the containment area (N = 8) (OR:
2.15, X2 P = 0.007), the small sample size limits the interpre-
tation of these results.
Figure 2. Pie charts to illustrate the types of artemisinin-containing antimalarials (ACAs) purchased through the census survey and mystery
client (MC) study.
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Expiry dates. From the census survey, 9.9% (21/212) of
drugs were found to be expired at the time of purchase with
expiry dates ranging back to June 2009. No expiry date infor-
mation was available for 3.3% (7/210) drugs. However, for
drug bought by MCs, there was no expiry date information
for 30.4% (24/79) drugs because they were sold outside of
their original packaging. From the expiry date information
that was available, 13.9% (11/79) drugs were expired at the
time of purchase. Therefore, MC-purchased ACAs had twice
the odds of being expired compared with those bought in the
census study (OR: 2.19, 95% CI: 0.88, 5.16, P= 0.05). There
was no association between stated brand name and whether a
sample was expired.
Packaging. From the inspection and comparison of the pack-
aging of the samples against available originals, there were no
obvious falsified packages. There were a number of locally
registered brands for which original packaging was not avail-
able to compare with; these included artesunate monotherapy
tablets (ArquineÒ and Artesunate from Bindinh pharma).
API content analysis. Two hundred and ninety one
artemisinin derivatives were analyzed by HPLC. The most
common form was artesunate tablets (80.1%, 233/291), most
(87.1%, 203/233) of which were co-blistered with mefloquine
with only one sample of co-formulated artesunate and meflo-
quine and the remainder 12.4% (29/233) of samples as the
monotherapy. The second most common form was injectable
artemether (12.4%, 36/291) followed by co-formulated tablets
of artemisinin and piperaquine (6.2%, 18/291).
All samples were found to contain the stated API (Figure 3).
Overall, 68.7% (N = 200/291) contained ³ 85% and < 115% of
the stated API and were considered of satisfactory quality for
single tablet analysis, and 31.3% (N = 91) of samples were
outside of this range and therefore considered poor quality
(data not shown).
A quarter of medicines (72/291) were expired at the time of
analysis, and of these, 40.3% (N = 29/72) were poor quality.
For the drugs that were not expired at the time of analysis,
26.1% (49/188) were poor quality. Forty drugs expired between
time of purchase and time of analysis but this did not affect the
proportions for poor-quality drugs (Table 2).
For quality control purposes, 14 artesunate and 11 meflo-
quine samples were sent to the Centers for Disease Control
and Prevention Laboratories, Atlanta, GA, for blinded interlab
assay comparison using HPLC. The correlation of the results
between both laboratories was high for both artesunate (r =
1.0) and mefloquine (r = 1.0) (data not shown). Overall, final
Figure 3. The percentage (mean and 95% confidence interval [CI]), of active pharmaceutical ingredient (API), as measured by high-
performance liquid chromatography (HPLC), for all artemisinin-containing antimalarials (ACAs) by census collection (black) (N = 212), mystery
client (MC) collection (grey) (N = 79), and overall (white) (N = 291). The proportion of samples that fell within the 85–115% API boundary is
outlined by a dashed line.
Table 2
Expiry status and quality of samples by collection method, at time of purchase and time of analysis
n (%)
All Census survey collection MC collection
Total 291 212 79
Of which poor quality 91 (31.3) 67 (31.6) 37 (30.4)
Status at time of purchase Expired 32 21 11
Of which poor quality 13 (40.6) 10 (47.6) 3 (27.3)
Not expired 228 184 44
Of which poor quality 65 (28.5) 55 (29.9) 10 (22.7)
Don’t know 31 7 24
Of which poor quality 13 (41.9) 2 (28.6) 11 (25.8)
Status at time of analysis Expired 72 53 19
Of which poor quality 29 (40.3) 24 (45.3) 5 (26.3)
Not expired 188 152 36
Of which poor quality 49 (26.1) 41 (27.0) 8 (22.2)
Don’t know 31 7 24
Of which poor quality 13 (41.9) 2 (28.6) 11 (45.8)
MC = mystery client.
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results from both laboratories were consistently within 3–4% of
each other and therefore considered unbiased.
By API type. Three quarters 74.2% (173/233) of the oral
artesunate tablets were of satisfactory quality (API ³ 85%
and < 115%). The tablets that were bought co-blistered with
mefloquine had twice the odds (OR: 2.29, P = 0.04, 95% CI:
0.9, 5.5) of being of satisfactory quality compared with arte-
sunate tablets that were bought on their own as a monotherapy
(Figure 4). For injectable artemether, of the 36 samples, only
half (52.8%, 95% CI: 35.6, 69.9) of the samples were of satis-
factory quality (Figure 5).
There was considerable intra-batch and inter-batch vari-
ability in %API content. There was a trend toward drug qual-
ity being much more consistent in the first-line ACT (i.e., A +M
and Malarine).
Partner drugs. A total of 225 partner drug samples were
analyzed. Of the 203 mefloquine samples, only 54 (25.6%)
were of satisfactory quality (API ³ 85% and < 115%) so that
for co-blistered-artesunate and mefloquine samples, when
both drugs were taken into account, only 22.7% (N = 46/203)
of samples contained the correct amount of API for both
drugs (Table 3). For the piperaquine, six of the 17, (35.3%)
samples were of satisfactory quality (Figure 6).
Survey method. Overall, MCs were not more likely than
overt surveyors to collect poor-quality drugs (OR: 0.94, 95%
CI: 0.51, 1.71, P = 0.84) except for artesunate monotherapy.
The samples bought by a MC were more likely to be of poor
quality than the few that were bought by a surveyor (OR
20.17 (95% CI: 1.84, 944.57, P = 0.002) (Supplemental Annex
Tables 1 and 2).
Risk factors for poor drug quality. Table 4 shows the results
of the bivariate and multivariate analysis for risk factors asso-
ciated with poor-quality ACAs as defined by an API of < 85%
or ³ 115%.
By bivariate analysis, four variables were significantly asso-
ciated with poor-quality ACAs: if the artemisinin derivative
form was any other than oral artesunate (OR 3.21 [95%
CI: 2.31, 4.48, P < 0.0001]); if the artesunate tablet was
obtained as a monotherapy rather than co-blistered with
mefloquine (OR 2.63 [95% CI: 1.34, 5.91, P = 0.010]); if the
medicine was anything other than Malarine, (OR: 2.41, [95%
CI: 1.26, 4.66, P = 0.012]); and if the medicine was in inject-
able form rather than tablet form (OR 2.63 [95% CI: 1.08,
6.42, P = 0.036]). There was no association between quality of
samples collected from outlets within or outside of the con-
tainment area, qualification of providers, or between drugs
that were stored inside a cabinet inside a shop compared with
medicines stored elsewhere.
Following multivariate regression analysis, two variables
were significant at P £ 0.05. Samples that were expired at the
time of analysis had 2.56 (95% CI: 1.29, 5.07, P = 0.011) odds
of being poor quality when compared with samples that were
Figure 4. The percentage (mean and 95% confidence interval [CI]), of active pharmaceutical ingredient (API), as measured by high-
performance liquid chromatography (HPLC), for artesunate tablets, sold alone as monotherapy (black) (N = 29), and co-blistered with mefloquine
(grey) (N = 204). The proportion of samples that fell within the 85–115% API boundary is outlined by a dashed line.
Table 3
API content of co-blistered artesunate and mefloquine tablets as measured by HPLC*
Artesunate tablets
Mefloquine tablets
0–44% API 45–54% API 55–64% API 65–74% API 75–84% API 85–94% API 95–104% API 105–114% API 115–120% API > 120% API Total
0–44% API 0 0 0 1 0 1 0 0 0 0 2
45–54% API 0 0 0 0 1 1 0 0 0 0 2
55–64% API 0 0 0 1 8 0 0 0 0 0 9
65–74% API 0 0 0 4 4 1 0 0 0 0 9
75–84% API 0 0 0 2 15 3 0 0 0 0 20
85–94% API 0 0 0 13 44 15 5 3 0 0 80
95–104% API 2 0 2 8 27 9 6 5 0 0 59
105–114% API 0 0 0 3 10 2 1 0 0 0 16
115–120% API 0 0 0 0 3 0 0 1 0 0 4
> 120% API 0 0 0 1 0 0 1 0 0 0 2
TOTAL 2 0 2 33 112 32 13 9 0 0 203
API = actual pharmaceutical ingredient; HPLC = high-performance liquid chromatography.
*The shaded area denotes samples where both of the components are considered good quality with an API ³ 85% or < 115%.
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not expired and samples that cost £ 3,500 riels (US$0.85) had
1.65 odds (95% CI: 1.00, 2.72, P = 0.049) of being poor quality.
DISCUSSION
The Thai–Cambodia border has been the epicenter for anti-
malarial resistance for several decades and is now the focus of
artemisinin resistance. Although there are many contributory
factors, it is likely that the widespread prevalence in the past
of artemisinin-based monotherapies and poor-quality antima-
larials have played a significant part in the emergence of
antimalarial drug resistance.
Recently, major efforts have been made to tackle the prob-
lem of poor-quality medicines through regulation, enforce-
ment, education, and communication campaigns. However,
there is a lack of detailed data documenting the impact of
these interventions and in differentiating between prevalence
of falsified medicines from other poor-quality medicines.
This is of particular importance as combating these prob-
lems requires different strategies.15,30 This study attempts to
address that gap. Furthermore, a randomized approach was
used in this study, in contrast to studies in the past, which have
adopted a convenience approach to sampling. Random sam-
pling is recommended to obtain reliable estimates of pre-
valence31; to date this method has only been used in a few
studies.17,19,27,32–35 Finally, this is the first study to compare
two different methodologies for procuring medicines; overt
survey versus a covert MC approach. Both methodologies
have their strengths and weaknesses. Samples bought overtly
by researchers may result in bias, due to shopkeepers holding
back the drugs that are more likely to be falsified or poor
quality. Purchasing drugs through MCs can avoid this poten-
tial bias but has other disadvantages, including limitations
in terms of the number of different types of drugs that can
be believably asked for.
Key finding and implication for policy practice and research.
Fortunately, in this study no suspected falsified drugs were
found and Malarine (the national first-line treatment of Pf
malaria in Cambodia) was by far the most widely available
antimalarial. This is extremely encouraging given the large
number of falsified antimalarials previously reported.4,21 In
addition, although some artesunate monotherapy was found,
its prevalence was far less than prior to the ban on their sale.
In addition, the quality of the artesunate tablets in the first-
line co-blistered artesunate and mefloquine product was
higher than in monotherapy products.
These findings are encouraging, suggesting a positive
impact from some of the efforts made through the contain-
ment program. However, a number of other concerns are
revealed. First, 31.3% of ACAs were considered poor quality
at time of analysis, of which the majority (93.4%) contained
too little rather than too much of the API. Around one tenth
Figure 6. The percentage (mean and 95% confidence interval [CI]) of active pharmaceutical ingredient (API), as measured by high-
performance liquid chromatography (HPLC), for mefloquine (black) (N = 204), piperaquine (grey) (N = 14), and total partner drug (white) (N = 218)
samples. The proportion of samples that fell within the 85–115% API boundary is outlined by a dashed line.
Figure 5. The percentage (mean and 95% confidence interval [CI]), of active pharmaceutical ingredient (API), as measured by high-
performance liquid chromatography (HPLC), for injectable artemether samples (N = 36). The proportion of samples that fell within the
85–115% API boundary is outlined by a dashed line.
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of medicines were past their expiry date at the time of pur-
chase and drugs and samples that were expired had more than
twice the odds of being poor quality.
The low levels of API found in poor-quality samples may be
due to the degradation rather than problems with production.
Medicines that were originally of good quality may degrade
and become poor quality during routine transport and storage,
especially if stored beyond their expiry date36 and if exposed to
extremes of humidity and temperature.12,37,38 Artemisinin
derivatives are inherently unstable and are very sensitive to
heat and humidity. It is therefore essential to minimize the
degradation process during transportation and storage to
ensure that drugs remain useful for their active shelf life.39
There are little data on the quality of drugs past their expiry
dates. However, in the absence of data, medicines used past
their expiry date should be regarded as poor quality as they
may be degraded.28 Future studies are needed to evaluate both
the quality and the stability of drugs over time under routine
storage conditions. However, in this current study, it is not
possible to determine the cause of poor quality.
Although there has been much publicity about falsified med-
icines, the problem of poor-quality medicines has received less
attention. However, it can be argued that they are as important
for development of drug resistance and much more wide-
spread.30,40 Falsified antimalarials often do not contain any of
the stated active ingredients at all, although sometimes they
can contain small quantities, possibly to evade detection. This
can be potentially lethal to patients with malaria who take
them in the belief that they are taking an effective antimalarial.
However, falsified ACAs that do not contain any active ingre-
dient do not exert selective artemisinin “drug pressure” on
parasites and therefore do not contribute to the development
of drug resistance. In contrast, poor-quality drugs and falsified
drugs, which do contain sub-therapeutic amounts of the API,
put the malaria patient in risk and also increase the risk of the
selection of drug-resistant parasites.12,15,16,37,41
Since the completion of this study, Cambodia has switched
its first-line treatment policy to the fixed dose combination of
dihydroartemisinin and piperaquine for both uncomplicated
Pf and Pv malaria. There were severe delays in the switch,
resulting in the continued use of co-blistered artesunate and
mefloquine and therefore the potential for patients to selec-
tively take artesunate as monotherapy.42 Although the switch
to a co-formulated ACT is welcome, there are some concerns
about the stability of dihydroartemisinin,43 therefore, the
quality of this product must be monitored closely.
Table 4
Bivariate (crude) and multivariate (adjusted) model of association between poor quality ACAs (as defined by API < 85% or ³ 115%) and
exposure variables
Total number
of samples
Number (%) of poor
quality samples
(API < 85% or ³ 115%)
Crude OR (95% CI) P value Adjusted OR (95% CI) P valueN = 291 N = 91 (%)
Collection method
Census 212 67 (31.6) 1.0 − − − − −
MC 79 24 (30.4) 0.96 (0.44, 2.08) 0.912 0.74 (0.31, 1.77) 0.471
Brand name
Malarine (all age groups) 178 44 (24.7) 1.0 − − − − −
Other brands 113 47 (41.6) 2.41 (1.26, 4.66) 0.012** 1.65 (0.69, 3.98) 0.236*
Dose form
Oral tablet 255 72 (28.2) 1.0 − − − − −
Liquid injection/ampoule 36 19 (52.8) 2.63 (1.08, 6.42) 0.036** 3.39 (0.94, 12.25) 0.061*
API
Artesunate 233 60 (25.8) 1.0 − − − − −
Other APIs 58 31 (53.5) 3.21 (2.31, 4.48) < 0.0001** 0.90 (0.22, 3.64) 0.877
Artesunate form†
Co-blister with Mefloquine 204 48 (23.5) 1.0 − − − − −
Artesunate monotherapy 29 12 (41.4) 2.81 (1.34, 5.91) 0.010** − − −
Location of outlet
Inside containment area 134 41 (30.6) 1.0 − − − − −
Outside containment area 157 50 (31.9) 1.09 (0.52, 2.26) 0.802 1.09 (0.63, 1.87) 0.740
Expired at time of analysis?
No 188 49 (26.1) 1.0 − − − − −
Yes 72 29 (40.3) 1.84 (0.92, 3.66) 0.080* 2.56 (1.29, 5.07) 0.011**
Price (Riel)
> 3,500 202 62 (30.7) 1.0 − − − − −
£ 3,500 77 27 (35.1) 1.16 (0.72, 1.88) 0.518 1.65 (1.00, 2.72) 0.049**
Qualification of outlet owner‡
No training 35 13 (37.1) 1.0 − − − − −
At least some training 100 30 (30.0) 0.73 (0.37, 1.41) 0.305 − − −
Storage conditions‡
Cabinet inside shop 192 60 (31.3) 1.0 − − − − −
Other storage conditions 16 7 (43.8) 1.71 (0.81, 3.60) 0.138* − − −
Type of outlet‡
Pharmacy 66 21 (31.8) 1.0 − − − − −
Other outlet types 142 46 (32.4) 1.03 (0.56, 1.87) 0.924 − − −
API = active pharmaceutical ingredient; ACAs = artemisinin-containing antimalarials; CI = confidence interval; OR = odds ratio.
*P £ 0.25.
**P < 0.05.
†Data collected for artesunate samples only.
‡Data collected during Census only.
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A second finding that deserves discussion is the widespread
availability of injectable artemether. Because it has been the
recommended first-line treatment of severe malaria, it was
not included in the ban on artemisinin-based monotherapies.
Injections and infusions are very popular in Cambodia, as
they are often perceived as being more powerful than oral
preparations.44 It is not known whether the ban on oral
artemisinins resulted in a shift to injectable preparations, but
previous surveys have shown that it has been widely available
since at least 2002.45–48 It could be argued that further
research is required to document whether patients who are
receiving injectable artemether are also receiving a full course
of an ACT, and if not, what measures should be taken to
ensure that they do. However, given the evidence of the supe-
riority of intravenous artesunate49,50 and the recognition that
complicated malaria should be treated in public health facili-
ties, it would be more advisable to ensure referral and effec-
tive treatment of severe malaria to public health facilities and
to discourage the use of parenteral artemisinins in the private
sector except for pre-referral.
This study also confirmed some previously documented
findings: the widespread availability of drug “cocktails” that
often contain partial courses of antimicrobials, and an associa-
tion between the cost of drugs and drug quality.51,52 Finally,
although overall there was no significant difference in the qual-
ity of medicines bought by the two approaches, there were
significant differences in the types of medicines bought. Less
oral artesunate monotherapy was bought by the overt sur-
veyors than MCs, perhaps reflecting providers’ awareness of
the ban on oral artemisinins and their reluctance to sell these
overtly through fears of being reported or judged. Conversely,
MCs obtained very few samples of injectable artemisinins as
these are usually administered to the patient by providers and
it was clearly ethically unacceptable to expect the MCs to
subject themselves to the pain and risks associated with receiv-
ing unnecessary injections! It may be that different approaches
are appropriate in different settings and further comparative
studies are required to accurately describe the true prevalence
of poor-quality medicines and establish standard methodologi-
cal approaches to sample collection.
This study had a number of limitations. First, the sample
size was relatively small. However, the selection was random-
ized and nationwide, and is therefore more robust and
generalisable than most of the previously published studies
on drug quality. Second, this study was only conducted in the
private sector and not in public health facilities where the
scale of the problem of expired and poor-quality drug remains
unknown and deserves attention. Third, the definition of a
threshold of poor quality drugs set at < 85% or ³ 115% API
may be criticized. Unfortunately, there is currently no accepted
definition for poor-quality drugs that can be used to compare
across different medicines. In the absence of an established
threshold, we used a range that we believe is justifiable based
on the USP guidelines, which allows for a wider range for
analysis of single tablets. Finally, a cross-sectional study such
as this only produces a snapshot in time and only reports on the
quality of ACAs. Clearly, what is required is the strengthening
of a routine surveillance system, which allows ongoing moni-
toring of all medicine quality. Much progress has been made in
Cambodia toward this end with the support of many interna-
tional partners including the WHO, Global Fund for AIDS,
Tuberculosis, and Malaria, U. S. Pharmacopeia, the French
embassy, USAID others. There is now strong multi-sectorial
support including involvement of the Ministries of Interior,
Police, Customs, and Education. However, the activities are
subject to the stops and starts inevitably associated with short-
term donor funding and other challenges including the lack of
laboratory and human resources.
These problems are not unique to Cambodia. Ensuring
that local drug regulatory agencies are strengthened and the
medicine manufacturing process is improved can help pre-
vent the problem of poor-quality antimalarials53; however,
there is limited knowledge on the geography and trading pat-
terns of poor quality medicines41,54 and, most importantly in
most malaria-endemic countries, the capacity of most drug
regulatory agencies is extremely limited allowing the manufac-
ture and sale of poor-quality medicines without the risk of
sanctions.30,40 There are insufficient testing facilities to analyze
antimalarial drugs and poor consumer and health worker
knowledge on drugs.55 The development and implementation
of new analytical tools, which can be used in the field by drug
inspectors and law enforcement officials are required to quickly
assess whether medicines are of good quality.56 Although a
number of alternatives are currently being explored, further
work is required to evaluate their operational accuracy and
feasibility.57–60 Whatever new tools are developed, there will
always be a need for local capacity to implement them.
Thirty percent of WHO member states have either no medi-
cine regulation or a capacity that hardly functions28 and only
20% have fully operational regulatory mechanisms to test the
quality specifications of medicines.30 Strengthening the capac-
ity of national medicine regulatory authorities is a global
health imperative.
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